Trial Profile

A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 27 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SGN CD228A (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; HER2 negative breast cancer; Malignant melanoma; Malignant-mesothelioma; Non-small cell lung cancer; Pancreatic ductal carcinoma; Skin cancer; Solid tumours
Focus Adverse reactions
Sponsors Seagen

Most Recent Events

21 Mar 2023 Status changed from active, no longer recruiting to discontinued.
23 Jan 2023 Status changed from recruiting to active, no longer recruiting.
23 Dec 2021 Planned number of patients changed from 290 to 210.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com